Biotech Values

[swampboots]

DTIL: (1.50's or lower target buying price) I am a sometimes investor as stock uses its shareholders to sponsor its expensive goals, But recent multiple handshakes with top tiered drug houses, insider buying, and recent share offering swallowed into current share price offered (to me) better safety than peers which lacked such a recent trifecta.
Highly notable to me and more comforting as an investor are the almost daily discoveries of new mechanisms which may introduce new solutions that for example may block or turn on or off influences which affect even approved CART-T safety and effectiveness. In my opinion, this implies that all Cart-T platforms have available outsource able safety nets to in theory most likely improve their platform in a significant profitable way, and made available to patients as long as the cost of their treatment has a market for their improved delivery system.
https://medicalxpress.com/news/2022-09-immune-cells-cancer.html?utm_source=
https://www.sciencedaily.com/releases/2022/09/220909191820.htm


(if a problem with the links) a copy and paste on Goggle did the trick for me.